Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : VD's Model Portfolio & Discussion Thread -- Ignore unavailable to you. Want to Upgrade?

To: Rocketman who wrote (5854)	10/31/1998 12:37:00 AM
From: Bluegreen	Respond to of 9719

Rman, you are probably old enough to remember how clinicians pushed the envelope with Beta blockers and Calcium channel blockers. Talk about off label usage! Clinicians worldwide are frothing at the mouth to push the envelope with the BPI molecule in the same fashion in my opinion. You think clinicians are concerned about official FDA indication? Especially when they are armed with BPI's safety profile? I would also think expense would probably be no more in today's dollar to treat than hospital emergency condition administration of Calcium channel blockers in their heyday. Sepsis, oh yeah, but what about synergistic effects when combined with antibiotics? How much of that decrease in mortality in Phase II Meningo. was due to rapid clearance of LPS or synergy with antibiotics administered? If you will take a quick look at collaborations being done worldwide just on BPI molecule you might be surprised. November issue of Discover magazine has some excellent reading on antimicrobial peptides and reasons why they are very difficult to get as Harmon was saying "high flying."

To: Rocketman who wrote (5854)	10/31/1998 2:26:00 AM
From: Vector1	Read Replies (1) \| Respond to of 9719

Rman, I just got back from a trip and I see that I missed a lot. We have been invaded by the XOMAnians. First in full dislosure I already own some XOMA. Unfortunately I paid $5 per share. I didn't want it in the portfolio because I felt quite ambivilent about the investment. My track record on stocks I am ambivilent on is quite poor and one of the lessons I have learned over the years is to stay away when you are ambivilent about a stock. In XOMAs case I am lured by the potential and the strong hope that they are succesful because it would be such a wonderful breakthrough in medical treatment. Sentimentalism can be very expensive in the stock market. Regarding AMLN please consider dumping the stock before we loose money. We are starting to kick ass with some first class companies. No need to look for life in the graveyard even if it is Halloween. Did you see the GENZ news on Hurlers. They reported positive results from a trial of alpha-L-iduronidase enzyme replacement therapy. According to the Dow Jones report in the trial, 10 pts with the fatal Hurler/Scheie disease, were treated for 26 weeks with a weekly IV infusion of 0.5mg/kg of the enzyme, which is involved in breakdown of complex carbohydrates. Patients showed improvement in MRI measures (reduction of liver size to normal), lab values (excretion of complex carbs) and quality of life (reduction of joint pain and breathing difficulty, improved mobility). Adverse effects were transient and did not impact treatment. The company and its partner Biomartin should get fast track approval and be approved in 1999. GENZ could have 3 new therapuedics approved in a 12 month stretch-- Thyrogen RenaGel and Alpha L. Yeah Baby. V1